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Introduction
Prostate cancer (PCa) is a major health care problem because of its high prevalence, health-related costs and mortality; this is even more in case of patients with high-risk disease. At PCa diagnosis, reported incidence rates of high-risk localised PCa vary between 17% (cT3a, PSA > 20 ng/ml, Gleason score (GS) ≥ 8) and 31% ( c2c-T3a, PSA(prostatespecific antigen) > 20 ng/ml, GS ≥ 8), depending on how this disease was defined 1 . After primary treatment, patients with high-risk localised PCa have a higher risk of disease recurrence and progression (e.g., PSA failure, need for secondary therapy, metastatic progression and PCa-related death) resulting in worse prognosis 2 . Despite the impact of this high-risk disease, a standardised definition is still lacking. D' Amico initially introduced a risk stratification based on three common available clinical features, by PSA, biopsy GS (bGS), clinical stage (cT) and defined high-risk localised PCa as PSA > 20 ng/ml or bGS ≥ 8 or cT2c 3 . After this, different definitions have been proposed by major scientific associations (e.g., European Association of Urology; American Urological Association; National Comprehensive Cancer Network, Radiation Therapy Oncology Group, Cancer of the Prostate Risk Assessment Score), but a general consensus remains absent 4 . 7, 8 . These findings indeed suggest that, while current high-risk localised PCa definitions are not sufficient to correctly define this heterogeneous group of patients, the outcomes are far surpassing those of conservative treatments.
Currently, there is a growing interest in the treatment of high-risk localised PCa and in defining the 'true' high-risk PCa patient. Therefore, the aim of this review article is to concisely describe the epidemiology of high-risk localised PCa and provide the latest evidence concerning the role of surgery and new prognostic tools in high-risk prostate cancer (HRPCa).
Discussion
The authors have referenced some of their own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies.
Diagnosis and incidence
PCa represents 28% of all cancer diagnoses in men, covering 50% of all diagnosed cancers together with lung/bronchus and colorectal cancers, which are the most common causes of death from malignant tumours in men 9 . Estimations show that in 2008 alone, 899,000 patients were diagnosed with PCa and 258,000 men died because of this disease worldwide. In 72% of cases, PCa was diagnosed in industrialised countries, but the highest mortality rates were reported in South America, the Caribbean and sub-Saharan 15 .
Natural history and surgical therapy
The natural course of high-risk localised or locally advanced PCa can be associated with very high mortality rates, as shown by the results of the Prostate Cancer Data Base Sweden study in which a cohort of 12,184 patients with localised and locally advanced PCacT3/4 or cT2 with PSA=50-99ng/ml were treated with non-curative intent. The 8-year PCSM was 52% for GS 8 and 64% for GS 9-10 disease irrespective of age; PCSM rates in patients aged > 85 years were still 42%. In every age group, GS was the strongest predictor of PCSM (GS ≥ 9 delete vs. GS 8: HR: 2.32 (95% CI: 2.07-2.61) 16 . More recently, a large study from the National Prostate Cancer Register of Sweden, analysing a cohort of 30,159 patients with HRPCa (cT3 or PSA: 20-<50 ng/ml or GS ≥ 8), found 15-year cumulative PCSM rates of 21.7 and 35.5% when treated with (EBRT (+ADT), RP + e-PLND) or without (ADT) curative intent, respectively. Mortality rates were highest in regionally (49.1%) and distant metastatic (69.5%) disease. These data emphasise the deadliness of this disease, which is greatly reduced when treated with curative intent, irrespective of age 6 . Even though it is clear that treatment with curative intent is of utmost importance in high-risk localised PCa, it is still heavily debated which is the optimal treatment option. The two major approaches are EBRT + ADT or RP + e-PLND; in many cases, 1 . The aims of surgery as primary treatment for high-risk localised PCa are local tumour control, staging and grading optimisation. This optimal staging has two purposes: firstly, it permits a more individualised approach and secondly prostate specimens may be used for research purposes. Surgery is not only interesting for its staging purposes, since there are also convincing data showing the efficiency of RP. Engel et al. analysed a cohort of 1,413 patients with node-positive disease and compared patients who did vs. those who did not undergo RP. They concluded that patients with node-positive disease in whom RP was abandoned, had a two times higher risk of overall mortality when compared to patients in whom RP was completed (HR: 2.04 (95% CI: 1.59-2.63; p < 0.0001) 17 . Supporting these results, a post-hoc analysis from the SPCG-4 trial, randomising patients with localised PCa to watchful waiting or RP, showed 10-year cumulative PCSM rates of 14.1 and 9.5% respectively; younger patients with more aggressive disease features had most benefit from surgery 18 . More recently, a large retrospective series on high-risk localised PCa patients treated by RP + e-PLND confirmed the excellent outcomes following surgery and showed that even senior adults with two to three high-risk factors without major co-morbidities had low CSM rates, comparable to younger patients. As expected, other cause mortality was the leading cause of death in this group, however without having an impact on CSM rates 19 . The PIVOT trial, randomising patients with localised PCa for RP vs. observation, showed significantly lower PCSM rates after performing surgery for patients with PSA > 10 ng/ml (5.6 vs. 12.8%; p = 0.02) and high-risk PCa (cT2c-3a, PSA > 20 ng/ml, GS ≥ 8; 9.1 vs. 17.5%; p = 0.04) when compared to observation 20 . Although there is sufficient evidence showing the efficacy of RP in patients with high-risk PCa, there is a paucity of evidence comparing different treatment options. In a retrospective analysis from the Memorial Sloan Kettering Cancer Centre (MSKCC), Zelefsky et al. suggested that RP + e-PLND had a better outcome when compared to intensity-modulated radiotherapy (IMRT; dose ≥81Gy), especially in high-risk localised PCa patients (8-year PCSM: RP 3.8 vs. IMRT 9.5%) 21 . Another large retrospective series by Boorjian et al. showed that HRPCa patients treated with EBRT alone (median dose 72Gy) had a higher risk of systemic progression (HR: 1.53; 95% CI: 1.05-2.23; p = 0.03) and PCSM (HR: 2.14; 95% CI 1.35-3.39; p = 0.001) when compared to patients undergoing RP 22 . To clearly define the optimal treatment option for localised high-risk PCa patients, there is an urgent need for a randomised clinical trial comparing radiotherapy and surgery. While interesting and highly needed, such study still might not provide all the answers to optimally guide treatment in each individual because of the heterogeneity of the disease. With the purpose of handling this major problem, many interesting biomarkers are being studied and implemented in order to help predict disease aggressiveness.
Review

The role of pre-operative predictive models
As discussed above, when evaluating outcomes of high-risk localised PCa after RP authors have used different definitions. Yossepowitch et al. assessed how accurately these definitions could identify patients likely to receive secondary cancer therapy, develop metastatic progression or die of PCa. They analysed these outcomes using different risk definitions in a cohort of 5960 patients from MSKCC who were surgically treated. Each of the studied high-risk definitions was associated with an increased risk of secondary cancer therapy and metastatic progression. Depending on the definition used, 35-76% of patients did not require additional therapy and 72-91% of patients did not develop metastasis 10 years after RP 8 . Comparing different treatment options is difficult because different classification systems are being used and because of the inter-observer variability of pre-treatment clinicopathological features.
Moreover, GS is down-graded (from biopsy to post-operative specimen) in up to 45% of cases and staging errors (higher pathological stage after surgery in 68% or down-staging from cT3 to pT2 tumours in 26%) are common [23] [24] [25] . For the diagnosis of extra-capsular disease and seminal vesicle invasion, magnetic resonance imaging performs better compared to digital rectal examination, which only has an accuracy of 60% 26 . Since pre-operative clinicopathological features in isolation are no optimal tools to predict tumour characteristics and disease outcomes, new predictive models have recently been proposed to predict specimen confined disease and lymph node invasion (LNI The clinico-pathological features used in these nomograms are still affected by the inter-observer variability. Even though current nomograms are useful at guiding decision making, the future lies within pre-operative biomarkers which have already shown to improve the accuracy of predictive models 29, 30 . Therefore, these data should stimulate continuing efforts in biomarker research, which could and will open new perspectives to a better and clinically useful risk stratification for PCa and identifying the 'true' high-risk patient.
Conclusion
PCa remains the most frequently diagnosed cancer among men with high-risk localised PCa representing an important subgroup. During the last decades, the incidence rates of high-risk localised and locally advanced PCa have decreased likely as a result of intensified PCa screening which has led to earlier diagnosis and treatment. However, when diagnosed with high-risk localised PCa, mortality is high if patients do not undergo treatment with curative intent. Currently, patients still too often receive hormonal treatment as monotherapy, a practice which is based on the historical belief that HRPCa cannot be cured. Recent evidence however shows excellent cancer-specific survival following RP, even in very high-risk patients with regional LNI. However, reported outcomes after RP vary significantly depending on the high-risk definition used and as a result of the interobserver variability of pre-treatment clinico-pathological features. Because of this heterogeneity, there is still no optimal treatment for the high-risk localised PCa patient, which does not only impact clinical practice but also has its effect on designing randomised trials comparing treatment options. Recently, several useful nomograms have been proposed in order to optimise the prognostic value of current clinico-pathological features. Nevertheless, while being useful and more accurate than clinical features in isolation, pre-treatment nomograms are still lacking sufficient accuracy. The future lies in the development of novel biomarkers and their introduction into nomograms, optimising pre-treatment risk stratification and identifying the 'true' high-risk PCa patient.
